The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Tagraxofusp for R/R myelofibrosis shows promise
Tagraxofusp (SL-401) is an anti-CD123 therapy that is FDA-approved for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Here Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX, outlines the results from a phase 1/2 trial of tagraxofusp for relapsed/refractory intermediate or high risk myelofibrosis (NCT02268253), a setting where this agent is also hoped to excel. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
